Dotan Center Events

The Varda and Boaz Dotan Research Center in Hemato-Oncology, Tel Aviv University events

Hematological Malignancies Research Horizons - The 4th Dotan International Symposium

New Approaches for Therapy of Hematological Malignancies Harnessing Biology to Cure Cancer - The 1^st Dotan International Symposium | 13.09.2016 | Beit Hatfutsot, Tel Aviv University Campus

The First Dotan Center International Symposium titled "New Approaches for Therapy of Hematological Malignancies" was held at the Tel Aviv University campus on September 13th 2016.

The symposium was initiated and is entirely funded by the Dotan Center. It dealt with translational research in the field of Hemato-Oncology and it has created a unique platform that has not yet been addressed in Israel.

The international symposium was attended by the following researchers:

Prof. Omar Abdel-Wahab from Memorial Sloan Kettering Cancer Center
Prof. Jean-Pierre Bourquin from University Zurich
Prof. Andreas Engert from University Hospital Colonge
Prof. Ronald Levy from Stanford University
Prof. Jonathan D. Licht from the University of Florida
Prof. Ari M. Melnick from Weill Cornell Medical College
Prof. Richard Moriggl from the Boltzmann Institute of Cancer research in Vienna
Prof. Veronika Sexl from the University of Veterinary Medicine of Vienna.
They were joined by six esteemed scientists from Israel:
Prof. Yinon Ben Neria from HUJI
Prof. Zelig Eshhar from Sourasky Medical Center
Elad Jacoby MD from Sheba Medical Center
Prof. Dan Peer from TAU
Prof. Yair Reisner from the Weizmann Institute of Science
Liran Shlush MD PhD from the Weizmann Institute of Science

The symposium focused on the two different approaches for targeting hematological malignancies; Targeting specific genes and pathways within the malignant cells or targeting the cancer phenotype, mainly by manipulating the immune system.

The participants described how their research has led or is about to lead to a revolution in the treatment of blood cancers. The symposium was a unique opportunity for the medical and scientific community at Tel Aviv University and in Israel as a whole to meet international hematological leaders (scientists and MDs) and to establish collaborations and joint ventures that aim to ultimately cure the range of hematological cancers.